Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.57 |
| ▸ | ELANE | P08246 | 4/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042503 | 0.92 | ALOX15 (0.66) | MAPTTSHRALOX15GFERADAM17 | |
| SCHEMBL2792367 | 0.89 | CES2 (0.58) | MAPTTSHRALOX15GFERADAM17 | |
| SCHEMBL4119062 | 0.87 | MAPT (0.56) | MAPTTSHRALOX15GFERADAM17 | |
| SCHEMBL30668123 | 0.85 | ATM (0.59) | MAPTTSHRSRD5A2ATMALDH1A1 | |
| SCHEMBL14033164 | 0.85 | ATM (0.59) | MAPTTSHRSRD5A2ATMALDH1A1 | |
| SCHEMBL11060916 | 0.85 | ALOX15 (0.58) | MAPTTSHRALOX15GFERADAM17 | |
| SCHEMBL10972254 | 0.83 | HPGD (0.59) | MAPTTSHRALOX15GFERADAM17 | |
| SCHEMBL2761797 | 0.82 | SRD5A2 (0.59) | SRD5A2ELANEATMALDH1A1STS | |
| SCHEMBL1018588 | 0.82 | KMT2A (0.64) | MAPTTSHRALOX15GFERADAM17 | |
| SCHEMBL10967959 | 0.81 | ALOX15 (0.50) | MAPTTSHRALOX15GFERADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113817086-B | Bio-based light-cured resin composition and preparation method and application thereof | 韦尔通(厦门)科技股份有限公司 | 2022-11-11 | — | — | CN | claimed |
| US-11760701-B2 | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YROK (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760701-B2 | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YROK (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210032181-A1 | DIFLUOROMETHOXYLATION AND TRIFLUOROMETHOXYLATION COMPOSITIONS AND METHODS FOR SYNTHESIZING SAME | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-02-04 | — | — | US | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1423381-B1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| US-4935414-A | New indolylpropanols, processes for their preparation and their use, and preparations containing the compounds | BEIERSDORF AG (DE) | 1990-06-19 | — | — | US | disclosed |
| EP-0297380-A2 | Indolyl propanols, process for their preparation, their uses and preparation containing them | Beiersdorf-Lilly GmbH (DE) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032181-A1 | DIFLUOROMETHOXYLATION AND TRIFLUOROMETHOXYLATION COMPOSITIONS AND METHODS FOR SYNTHESIZING SAME | AFF2, AFF4, AFF1 | MAPT 2445/4885TSHR 2337/4885ALOX15 3276/4885 |
| US-11760701-B2 | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same | AFF2, AFF4, AFF1 | MAPT 2445/4885TSHR 2337/4885ALOX15 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.